Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer

eLife

Volumn 3, Issue November, 2014, Pages 1-23

  Yizhak, Keren ^a   Gaude, Edoardo ^b   Le Dévédec, Sylvia ^c   Waldman, Yedael Y ^a   Stein, Gideon Y ^a,d   van de Water, Bob ^c   Frezza, Christian ^b   Ruppin, Eytan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c LEIDEN UNIVERSITY   (Netherlands)

^d RABIN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENZYME; GLUTATHIONE; MALONYL COA DECAYBOXYLASE; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBOXYLYASE; FATTY ACID; MALONYL-COA DECARBOXYLASE; TUMOR MARKER;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG RESPONSE; DRUG SELECTIVITY; GENE SILENCING; GROWTH RATE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLOMICS; NEOPLASM; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIMULATION; VALIDATION PROCESS; BIOSYNTHESIS; CITRIC ACID CYCLE; DRUG EFFECTS; HUMAN GENOME; LYMPHOCYTE; NEOPLASMS; OXIDATION REDUCTION REACTION; PATHOLOGY; PERSONALIZED MEDICINE; TUMOR CELL LINE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; CARBOXY-LYASES; CELL LINE, TUMOR; CELL PROLIFERATION; CITRIC ACID CYCLE; FATTY ACIDS; GENE KNOCKDOWN TECHNIQUES; GENOME, HUMAN; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHOCYTES; MODELS, BIOLOGICAL; NEOPLASMS; OXIDATION-REDUCTION; PHENOTYPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84930377006     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.03641     Document Type: Article

References (58)

1. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J. 2012. Reconstruction of genome-scale active metabolic Networks for 69 human cell Types and 16 Cancer types using INIT. PLOS Computational Biology 8:e1002518. doi: 10.1371/journal.pcbi.1002518.
2. Agren R, Mardinoglu A, Asplund A, Kampf C, Uhlen M, Nielsen J. 2014. Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Molecular Systems Biology 10:721. doi: 10.1002/msb.145122.
3. Berg JM, Tymoczko JL, Stryer L. 2002. Fatty acids are synthesized and degraded by different pathways. 5th edition. Biochemistry. New York: WH Freeman.
4. Bordel S, Agren R, Nielsen J. 2010. Sampling the solution space in genome-scale metabolic networks reveals transcriptional regulation in key enzymes. PLOS Computational Biology 6:e1000859. doi: 10.1371/journal. pcbi.1000859.
5. Bouzakri K, Austin R, Rune A, Lassman ME, Garcia-Roves PM, Berger JP, Krook A, Chibalin AV, Zhang BB, Zierath JR. 2008. Malonyl Coenzyme A decarboxylase regulates lipid and glucose metabolism in human skeletal muscle. Diabetes 57:1508-1516. doi: 10.2337/db07-0583.
6. Burgard AP, Pharkya P, Maranas CD. 2003. Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnology and Bioengineering 84:647-657. doi: 10.1002/bit.10803.
7. Chandrasekaran S, Price ND. 2010. Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of USA 107:17845-17850. doi: 10.1073/pnas.1005139107.
8. Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ. 2010. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLOS Computational Biology 6:e1000938. doi: 10.1371/journal. pcbi.1000938.
9. Cheong H, Lu C, Lindsten T, Thompson CB. 2012. Therapeutic targets in cancer cell metabolism and autophagy. Nature Biotechnology 30:671-678. doi: 10.1038/nbt.2285.
10. Choy E, Yelensky R, Bonakdar S, Plenge RM, Saxena R, De Jager PL, Shaw SY, Wolfish CS, Slavik JM, Cotsapas C, Rivas M, Dermitzakis ET, Cahir-McFarland E, Kieff E, Hafler D, Daly MJ, Altshuler D. 2008. Genetic analysis of human traits in vitro: drug response and gene expression in Lymphoblastoid cell lines. PLOS Genetics 4:e1000287. doi: 10.1371/journal.pgen.1000287.
11. Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, Cheng TY, Moody DB, Murray M, Galagan JE. 2009. Interpreting expression data with metabolic flux models: predicting mycobacterium tuberculosis mycolic acid production. PLOS Computational Biology 5:e1000489. doi: 10.1371/journal.pcbi.1000489.
12. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, METABRIC Group, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale AL, Brenton JD, Tavaré S, Caldas C, Aparicio S. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346-352. doi: 10.1038/nature10983.
13. Dolfi S, Chan LL, Qiu J, Tedeschi PM, Bertino JR, Hirshfield KM, Oltvai ZN, Vazquez A. 2013. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism 1:20. doi: 10.1186/2049-3002-1-20.
14. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, Srivas R, Palsson BØ. 2007. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proceedings of the National Academy of Sciences of USA 104:1777-1782. doi: 10.1073/pnas.0610772104.
15. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arrhenius T, Harmon C, Yang G, Nadzan AM, Lopaschuk GD. 2004. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circulation Research 94:e78-e84. doi: 10.1161/ 01.RES.0000129255.19569.8f.
16. Facchetti G, Zampieri M, Altafini C. 2012. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer. BMC Systems Biology 6:115. doi: 10.1186/1752-0509-6-115.
17. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. 2014. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510:298-302. doi: 10.1038/nature13236.
18. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. 2011. Predicting selective drug targets in cancer through metabolic networks. Molecular Systems Biology 7:501. doi: 10.1038/msb.2011.35.
19. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E. 2011. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477:225-228. doi: 10.1038/nature10363.
20. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575. doi: 10.1038/nature11005.
21. Grambsch TMTP. 2000. Modeling survival data: extending the Cox Model. Springer.
22. Holbeck SL, Collins JM, Doroshow JH. 2010. Analysis of food and drug administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Molecular Cancer Therapeutics 9:1451-1460. doi: 10.1158/1535-7163.MCT-10-0106.
23. International Hap Map Consortium. 2005. A haplotype map of the human genome. Nature 27:1299-1320. doi: 10.1038/nature04226.
24. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. 2012. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336: 1040-1044. doi: 10.1126/science.1218595.
25. Jensen PA, Papin JA. 2010. Functional integration of a metabolic network model and expression data without arbitrary thresholding. Bioinformatics 27:541-547. doi: 10.1093/bioinformatics/btq702.
26. Jerby L, Shlomi T, Ruppin E. 2010. Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Molecular Systems Biology 6:401. doi: 10.1038/msb.2010.56.
27. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53:457-481. doi: 10.1080/01621459.1958.10501452.
28. Lee D, Smallbone K, Dunn WB, Murabito E, Winder CL, Kell DB, Mendes P, Swainston N. 2012. Improving metabolic flux predictions using absolute gene expression data. BMC Systems Biology 6:73. doi: 10.1186/1752-0509-6-73.
29. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. 2007. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proceedings of the National Academy of Sciences of USA 104:13086-13091. doi: 10.1073/pnas.0610292104.
30. Lerman JA, Hyduke DR, Latif H, Portnoy VA, Lewis NE, Orth JD, Schrimpe-Rutledge AC, Smith RD, Adkins JN, Zengler K, Palsson BO. 2012. In silico method for modelling metabolism and gene product expression at genome scale. Nature Communications 3:929. doi: 10.1038/ncomms1928.
31. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, Patel N, Yee A, Lewis RA, Eils R, König R, Palsson BØ. 2010. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nature Biotechnology 28:1279-1285. doi: 10.1038/nbt.1711.
32. Lock EF, Abdo N, Huang R, Xia M, Kosyk O, O'Shea SH, Zhou YH, Sedykh A, Tropsha A, Austin CP, Tice RR, Wright FA, Rusyn I. 2012. Quantitative high-throughput screening for chemical toxicity in a population-based in vitro model. Toxicological Sciences 126:578-588. doi: 10.1093/toxsci/kfs023.
33. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, Goryanin I. 2007. The Edinburgh human metabolic network reconstruction and its functional analysis. Molecular Systems Biology 3:135. doi: 10.1038/msb4100177.
34. Mardinoglu A, Agren R, Kampf C, Asplund A, Uhlen M, Nielsen J. 2014. Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease. Nature Communications 5:3083. doi: 10.1038/ncomms4083.
35. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. 2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences of USA 102:13550-13555. doi: 10.1073/ pnas.0506230102.
36. Oberhardt MA, Palsson BO, Papin JA. 2009. Applications of genome-scale metabolic reconstructions. Molecular Systems Biology 5:320. doi: 10.1038/msb.2009.77.
37. Oberhardt MA, Yizhak K, Ruppin E. 2013. Metabolically re-modeling the drug pipeline. Current Opinion in Pharmacology 13:778-785. doi: 10.1016/j.coph.2013.05.006.
38. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, Furuta K, Tsuta K, Shibata T, Yamamoto S, Watanabe S, Sakamoto H, Kumamoto K, Takenoshita S, Gotoh N, Mizuno H, Sarai A, Kawano S, Yamaguchi R, Miyano S, Yokota J. 2012. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung Adenocarcinomas. Cancer Research 72:100-111. doi: 10.1158/0008-5472.CAN-11-1403.
39. Pey J, Rubio A, Theodoropoulos C, Cascante M, Planes FJ. 2012. Integrating tracer-based metabolomics data and metabolic fluxes in a linear fashion via Elementary Carbon Modes. Metabolic Engineering 14:344-353. doi: 10.1016/j.ymben.2012.03.011.
40. Polinati PP, Valanne L, Tyni T. 2014. Malonyl-Co A decarboxylase deficiency: long-term follow-up of a patient new clinical features and novel mutations. Brain and Development S0387-7604:00039-00034. doi: 10.1016/j. braindev.2014.02.001.
41. Price ND, Reed JL, Palsson BO. 2004. Genome-scale models of microbial cells: evaluating the consequences of constraints. Nature Reviews Microbiolgy 2:886-897. doi: 10.1038/nrmicro1023.
42. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN. 2000. A gene expression database for the molecular pharmacology of cancer. Nature Genetics 24:236-244. doi: 10.1038/73439.
43. Schuetz R, Zamboni N, Zampieri M, Heinemann M, Sauer U. 2012. Multidimensional optimality of microbial metabolism. Science 336:601-604. doi: 10.1126/science.1216882.
44. Segre D, Vitkup D, Church GM. 2002. Analysis of optimality in natural and perturbed metabolic networks. Proceedings of the National Academy of Sciences of USA 99:15112-15117. doi: 10.1073/pnas.232349399.
45. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E. 2011. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the warburg effect. PLOS Computational Biology 7:e1002018. doi: 10.1371/journal.pcbi.1002018.
46. Shlomi T, Cabili MN, Herrgård MJ, Palsson BØ, Ruppin E. 2008. Network-based prediction of human tissue-specific metabolism. Nature Biotechnology 26:1003-1010. doi: 10.1038/nbt.1487.
47. Simon R, Roychowdhury S. 2013. Implementing personalized cancer genomics in clinical trials. Nature Reviews Drug Discovery 12:358-369. doi: 10.1038/nrd3979.
48. Stark AL, Zhang W, Zhou T, O'Donnell PH, Beiswanger CM, Huang RS, Cox NJ, Dolan ME. 2010. Population differences in the rate of proliferation of international Hap Map cell lines. The American Journal of Human Genetics 87:829-833. doi: 10.1016/j.ajhg.2010.10.018.
49. Szappanos B, Kovács K, Szamecz B, Honti F, Costanzo M, Baryshnikova A, Gelius-Dietrich G, Lercher MJ, Jelasity M, Myers CL, Andrews BJ, Boone C, Oliver SG, Pál C, Papp B. 2011. An integrated approach to characterize genetic interaction networks in yeast metabolism. Nature Genetics 43:656-662. doi: 10.1038/ng.846.
50. Thiele I, Swainston N, Fleming RM, Hoppe A, Sahoo S, Aurich MK, Haraldsdottir H, Mo ML, Rolfsson O, Stobbe MD, Thorleifsson SG, Agren R, Bölling C, Bordel S, Chavali AK, Dobson P, Dunn WB, Endler L, Hala D, Hucka M, Hull D, Jameson D, Jamshidi N, Jonsson JJ, Juty N, Keating S, Nookaew I, Le Novère N, Malys N, Mazein A, Papin JA, Price ND, Selkov E Snr, Sigurdsson MI, Simeonidis E, Sonnenschein N, Smallbone K, Sorokin A, van Beek JH, Weichart D, Goryanin I, Nielsen J, Westerhoff HV, Kell DB, Mendes P, Palsson BØ. 2013. A community-driven global reconstruction of human metabolism. Nature Biotechnology 31:419-425. doi: 10.1038/nbt.2488.
51. Varma A, Palsson BO. 1994. Metabolic flux balancing: basic concepts, scientific and practical use. Nature Biotechnology 12:994-998. doi: 10.1038/nbt1094-994.
52. Wang Y, Eddy J, Price N. 2012. Reconstruction of genome-scale metabolic models for 126 human tissues using m CADRE. BMC Systems Biology 6:153. doi: 10.1186/1752-0509-6-153.
53. Wessely F, Bartl M, Guthke R, Li P, Schuster S, Kaleta C. 2011. Optimal regulatory strategies for metabolic pathways in Escherichia coli depending on protein costs. Molecular Systems Biology 7:515. doi: 10.1038/ msb.2011.46.
54. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. 2008. Drug Bank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Research 36:D901-D906. doi: 10.1093/ nar/gkm958.
55. Wu H, Zhu Q, Cai M, Tong X, Liu D, Huang J, Yang G, Jiang Y. 2014. Effect of inhibiting malonyl-coa decarboxylase on cardiac remodeling after myocardial infarction in rats. Cardiology 127:236-244. doi: 10.1159/000356471.
56. Yizhak K, Gabay O, Cohen H, Ruppin E. 2013. Model-based identification of drug targets that revert disrupted metabolism and its application to ageing. Nature Communications 4:2632. doi: 10.1038/ncomms3632.
57. Yizhak K, Le Dévédec SE, Rogkoti VM, Baenke F, de Boer VC, Frezza C, Schulze A, van de Water B, Ruppin E. 2014. A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration. Molecular Systems Biology 10:744. doi: 10.15252/msb.20134993.
58. Zhou W, Tu Y, Simpson PJ, Kuhajda FP. 2009. Malonyl-Co A decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene 28:2979-2987. doi: 10.1038/onc.2009.160.